Aclarion CEO Brent Ness to Participate in LSI USA 2026 Conference

March 12, 2026 — Aclarion, Inc., a healthcare technology company focused on advancing diagnostic solutions for spine-related conditions, has announced that its Chief Executive Officer Brent Ness will attend the LSI USA 2026 conference. The prestigious industry event brings together leaders, innovators, investors, and entrepreneurs across the global medical technology ecosystem.

The event serves as a significant platform for emerging medical technology companies to share their innovations, build strategic partnerships, and discuss the future of healthcare technology. Aclarion’s participation reflects its commitment to expanding collaboration and increasing awareness of its advanced diagnostic platform designed to address chronic low back pain.

About Aclarion, Inc.

Aclarion, Inc. is a medical technology company dedicated to improving how physicians diagnose and treat chronic spinal conditions. By leveraging advanced imaging technologies and sophisticated data analysis, the company aims to transform the way healthcare professionals identify the sources of back pain.

The company's proprietary technology focuses on analyzing metabolic biomarkers within spinal discs using magnetic resonance spectroscopy (MRS). This approach helps physicians differentiate between painful and non-painful discs, providing valuable insights that can improve treatment planning and patient outcomes.

One of Aclarion’s core innovations is its cloud-based analytics platform, which processes raw imaging data collected during standard MRI scans. Through proprietary signal processing and augmented intelligence algorithms, the platform converts complex spectral information into actionable clinical insights.

This data-driven approach supports clinicians in making more informed treatment decisions for patients suffering from chronic lower back pain, a condition affecting millions of people worldwide.

The Significance of LSI USA 2026

The LSI USA conference is widely recognized as one of the most influential gatherings in the global medtech industry. Organized by Life Science Intelligence (LSI), the event attracts a wide range of participants including:

• Medical technology startups
• Established medtech companies
• Institutional investors
• Venture capital firms
• Healthcare innovators
• Industry experts

The conference provides opportunities for companies to present groundbreaking technologies, engage with investors, and discuss emerging trends shaping the future of healthcare.

By participating in the event, Aclarion gains the opportunity to highlight its advanced diagnostic solutions and connect with potential partners who share a vision of improving spine care through innovative technology.

Brent Ness: Leadership Driving MedTech Innovation

As CEO of Aclarion, Brent Ness brings nearly three decades of experience in the medical technology sector. Throughout his career, he has played a pivotal role in commercializing innovative healthcare solutions across imaging, diagnostics, and software-as-a-service (SaaS) platforms.

Under Ness’s leadership, Aclarion has continued to expand its presence in the spine diagnostics field while advancing its flagship technologies designed to address the challenges of diagnosing chronic low back pain.

Ness is known for his expertise in building strategic partnerships, driving product adoption, and guiding healthcare technology companies through critical growth phases.

His participation in LSI USA 2026 is expected to reinforce Aclarion’s commitment to innovation and industry collaboration.

Addressing the Global Challenge of Chronic Low Back Pain

Chronic low back pain remains one of the most common medical conditions worldwide. Millions of patients experience persistent pain that significantly impacts their quality of life, productivity, and overall health.

One of the primary challenges in treating chronic back pain is accurately identifying the specific spinal disc responsible for the pain. Traditional imaging methods such as standard MRI scans can provide structural information but often fail to determine whether a particular disc is the true source of pain.

Aclarion’s technology seeks to address this gap by analyzing metabolic biomarkers within spinal discs. By providing deeper insight into disc physiology, the platform helps physicians distinguish between symptomatic and asymptomatic discs.

This capability may help reduce unnecessary procedures and enable more targeted treatments, ultimately improving outcomes for patients.

The Role of MR Spectroscopy in Spine Diagnostics

Magnetic Resonance Spectroscopy (MRS) is an advanced imaging technique that allows clinicians to analyze the chemical composition of tissues. Unlike traditional MRI, which focuses primarily on structural images, MRS can reveal metabolic activity inside tissues.

Aclarion utilizes this technology to measure specific biomarkers associated with disc degeneration and pain.

The company’s software platform interprets these complex signals and translates them into clear metrics that physicians can use to guide clinical decisions.

This approach represents a significant advancement in precision medicine for spine care.

Nociscan Platform: Transforming Spine Care

Aclarion’s flagship diagnostic platform, often associated with its Nociscan technology suite, converts MR spectroscopy data into actionable insights for clinicians.

The platform performs several key functions:

• Processing raw spectral imaging data
• Identifying metabolic biomarkers linked to disc pain
• Providing disc-specific diagnostic metrics
• Supporting clinical decision-making

By combining imaging science with cloud-based analytics and augmented intelligence, the platform helps physicians better understand the biological drivers of spinal pain.

This approach represents a shift toward more personalized and evidence-based treatment planning.

Strategic Importance of Industry Conferences

Industry events like LSI USA play a crucial role in the medical technology ecosystem. These conferences provide a venue where innovators can share ideas, demonstrate technologies, and foster collaboration across the healthcare industry.

For companies like Aclarion, participation in these events helps raise awareness of their technologies among key stakeholders, including clinicians, investors, and potential strategic partners.

Such visibility is essential for emerging healthcare technologies seeking broader adoption.

Investment Opportunities in the MedTech Sector

The global medical technology industry continues to experience rapid growth driven by innovation in diagnostics, imaging, digital health, and artificial intelligence.

Events like LSI USA are particularly valuable for investors seeking early access to promising healthcare technologies.

Aclarion’s presence at the conference highlights its role within the evolving spine diagnostics market and its potential to contribute to the next generation of healthcare innovation.

Collaboration Across the Healthcare Ecosystem

Healthcare innovation often requires collaboration among multiple stakeholders, including technology companies, clinicians, hospitals, academic researchers, and investors.

By attending LSI USA 2026, Aclarion aims to strengthen relationships across this ecosystem.

These partnerships are essential for advancing new diagnostic tools, conducting clinical research, and expanding access to improved healthcare solutions.

The Future of Spine Diagnostics

The field of spine diagnostics is undergoing significant transformation as new technologies enable deeper insights into the biological causes of pain.

Advanced imaging techniques, artificial intelligence, and data analytics are increasingly being integrated to support more accurate diagnoses.

Aclarion’s work represents a step toward this future, where clinicians can rely on objective biomarkers to guide treatment decisions.

This shift may ultimately lead to better outcomes for patients and more efficient healthcare systems.

Expanding Global Awareness of Innovative Diagnostics

Participation in international industry conferences also allows companies to expand their global reach.

As awareness of Aclarion’s technology grows, more healthcare providers may explore the potential benefits of integrating advanced metabolic imaging into their clinical workflows.

This broader awareness is essential for accelerating the adoption of next-generation diagnostic technologies.

Looking Ahead

Aclarion’s participation in LSI USA 2026 marks another milestone in the company’s ongoing efforts to transform spine diagnostics.

With continued innovation, strategic partnerships, and industry engagement, the company aims to advance its mission of improving outcomes for patients suffering from chronic back pain.

The conference will provide an opportunity for Aclarion’s leadership to engage with industry peers, discuss emerging trends in healthcare technology, and share insights about the future of precision diagnostics.

As the global medtech sector continues to evolve, companies like Aclarion are helping to shape a new era of data-driven healthcare.

For more information about Aclarion and its diagnostic technology, visit the company’s official website at https://www.aclarion.com.

#Aclarion #MedTechInnovation #SpineDiagnostics #LSIUSA2026 #SlimScan #GrowthStocks #CANSLIM